文献速递心脑血管急症重症综合管理与镇静镇痛

定量血流分数指导与血管造影指导经皮冠状动脉介入治疗:FAVOR III China 试验的二次分析

Quantitative Flow Ratio- vs Angiography-Guided Percutaneous Coronary Intervention: A Secondary Analysis of the FAVOR III China Trial.
PubMed 文献 · JAMA Netw Open · 2026-10-01
一句话结论在 FAVOR III China 试验的预设二次分析中,QFR 指导 PCI 与 3 年 MACE 较低相关,且治疗效应未因多支血管病变状态显著不同(P for interaction = .35)。

FAVOR III China 试验预设二次分析纳入 3825 例接受 PCI 的患者,其中 2066 例(54.0%)为多支血管病变(MVD)。比较 QFR 指导与血管造影指导下 PCI 的 3 年 MACE。MVD 队列中,QFR 指导组 3 年 MACE 发生率为 12.1%,血管造影指导组为 18.1%(HR 0.65,95% CI 0.52-0.81,P < .001);非 MVD 队列中分别为 8.6% 和 11.0%(HR 0.77,95% CI 0.57-1.04,P = .09)。治疗与 MVD 状态的交互作用不显著。

要点

  • 在 MVD 队列中,QFR 指导组 3 年 MACE 为 124/1023(12.1%),血管造影指导组为 188/1043(18.1%),HR 0.65(95% CI 0.52-0.81,P < .001)。
  • 在非 MVD 队列中,QFR 指导组 3 年 MACE 为 76/890(8.6%),血管造影指导组为 95/869(11.0%),HR 0.77(95% CI 0.57-1.04,P = .09)。
  • 治疗 × MVD 状态交互作用不显著(P for interaction = .35),提示 QFR 指导的获益方向在不同 MVD 状态间一致。
  • QFR 指导组 MACE 降低主要由心肌梗死和血运重建事件减少驱动。
  • landmark、符合方案、竞争风险、敏感性及层级胜出比分析均与主要结果方向一致。

适用人群与场景

  • 来自中国 26 个中心、2018 年 12 月 25 日至 2020 年 1 月 19 日筛选的成人 PCI 患者,共 3825 例,平均年龄 62.7 岁(SD 10.0),男性 2699 例(70.6%)。
  • 纳入标准:因稳定型或不稳定型心绞痛接受 PCI,或筛选前至少 72 小时发生心肌梗死的患者,且至少有 1 处直径狭窄 50%~90%、血管直径 ≥2.5 mm 的病变。

诊断标准与关键阈值

  • MVD 定义:至少累及 2 支心外膜血管或左主干冠状动脉。
  • 主要终点 MACE 定义为全因死亡、心肌梗死和缺血驱动的血运重建的复合终点。
  • 原文未提及 QFR 指导 PCI 的具体 QFR 截断值或血运重建决策阈值。

处置流程与药物剂量

  • 原文未提及具体的处置流程、药物剂量、给药途径或目标值。
  • 干预措施为随机 1:1 分配至 QFR 指导 PCI 或血管造影指导 PCI。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:FAVOR III China 随机临床试验的预设二次分析,26 个中心。
  • MVD 队列:QFR 指导组 MACE 发生率 12.1%,血管造影指导组 18.1%,HR 0.65(95% CI 0.52-0.81,P < .001)。
  • 非 MVD 队列:QFR 指导组 MACE 发生率 8.6%,血管造影指导组 11.0%,HR 0.77(95% CI 0.57-1.04,P = .09)。
  • 治疗 × MVD 交互作用不显著(P for interaction = .35)。
  • MACE 降低主要由心肌梗死和血运重建事件减少驱动。
  • landmark、符合方案、竞争风险、敏感性及层级胜出比分析结果与主要发现方向一致。
  • 试验注册:ClinicalTrials.gov Identifier NCT03656848。

证据类型、等级与局限

  • 证据类型:随机临床试验的预设二次分析。
  • 局限:原文未提及具体局限;二次分析中非 MVD 队列的组间差异无统计学意义。

对床旁实践的改变

  • 本结果提供 QFR 指导 PCI 在 MVD 和非 MVD 分层中的 3 年随机对照证据。
  • 交互作用不显著,提示不应基于 MVD 状态对 QFR 指导 PCI 的获益作截然不同的床旁推断。
  • 原文未提及改变急诊或 ICU 具体操作的直接推荐;这些结果需进一步验证。

指南或共识出处

  • FAVOR III China Randomized Clinical Trial; ClinicalTrials.gov Identifier: NCT03656848。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Whether the association of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) with long-term outcomes differs according to multivessel disease (MVD) status is uncertain.

OBJECTIVE: To assess the association of QFR-guided vs angiography-guided PCI with 3-year outcomes according to MVD status.

DESIGN, SETTING, AND PARTICIPANTS: In this prespecified secondary analysis of the FAVOR III China randomized clinical trial, patients were screened across 26 centers in China from December 25, 2018, to January 19, 2020. Eligible participants were adults undergoing PCI for stable or unstable angina or for myocardial infarction (MI) occurring at least 72 hours before screening who had at least 1 lesion with 50% to 90% diameter stenosis in a vessel of 2.5 mm or larger. The analysis compared QFR-guided with angiography-guided PCI according to MVD status. MVD was defined by involvement of at least 2 epicardial vessels or the left main coronary artery. The primary analyses of the current prespecified secondary analysis were completed in October 2024.

INTERVENTIONS: Randomization 1:1 to QFR-guided PCI or angiography-guided PCI.

MAIN OUTCOMES AND MEASURES: The primary end point of the FAVOR III China randomized clinical trial was 1-year major adverse cardiac events (MACE), defined as a composite of all-cause death, MI, and ischemia-driven revascularization. The current analysis evaluated 3-year MACE.

RESULTS: Among 3825 patients in the intention-to-treat population (mean [SD] age, 62.7 [10.0] years; 2699 [70.6%] male), 2066 (54.0%) had MVD. In the MVD cohort, MACE occurred in 124 of 1023 patients (12.1%) in the QFR-guided group and 188 of 1043 patients (18.1%) in the angiography-guided group (hazard ratio, 0.65; 95% CI, 0.52-0.81; P < .001), driven by lower rates of MI and revascularization. In the non-MVD cohort, MACE occurred in 76 of 890 patients (8.6%) and 95 of 869 patients (11.0%), respectively (hazard ratio, 0.77; 95% CI, 0.57-1.04; P = .09). The treatment × MVD interaction was not statistically significant (P for interaction = .35). The findings of landmark, per-protocol, competing-risk, sensitivity, and hierarchical win-ratio analyses were directionally consistent with the main findings.

CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of a randomized clinical trial of patients undergoing PCI, QFR-guided PCI was associated with a lower 3-year MACE rate among patients with MVD; however, no significant interaction was observed between treatment effect and MVD status. These findings provide longer-term randomized evidence supporting QFR-guided PCI across MVD strata and warrant further confirmation.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03656848.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Zhang, Shi, Guan, et al. Quantitative Flow Ratio- vs Angiography-Guided Percutaneous Coronary Intervention: A Secondary Analysis of the FAVOR III China Trial. JAMA Netw Open. 2026. PMID: 42911591. doi:10.1001/jamanetworkopen.2026.39926

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。